(E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
For research use only. We do not sell to patients.
- CAS No.: 69304-49-0
- Formula: C6H5BrN2O2
- Molecular Weight:217.02
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W012017
2-Hydroxytetradecanoic acidAntiviral -
HY-17422
AcyclovirHSV Inhibitor -
HY-W041343
4-Benzoylbenzoic acidPhotooxidant -
HY-17422R
Acyclovir (Standard)HSV Inhibitor -
HY-17425A
Valacyclovir hydrochlorideAntiviral Agent -
HY-W012017R
2-Hydroxytetradecanoic acid (Standard)Anti-virus Agent -
HY-17425AR
Valacyclovir hydrochloride (Standard)Antiviral Agent
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 69304-49-0
-
Molecular Weight 217.02
-
Formula C6H5BrN2O2
-
SMILES
O=C1NC(C(/C=C/Br)=CN1)=O
-
Synonyms
(E)-5-(2-Bromovinyl)uracil; BVU
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione Related Classifications
HY-W014109 Related Classifications
Powered by Bioz